Literature DB >> 12824997

Fetal fibronectin: the impact of a rapid test on the treatment of women with preterm labor symptoms.

Melanie M Plaut1, Wendy Smith, Kathleen Kennedy.   

Abstract

OBJECTIVE: The purpose of this study was to determine whether knowledge of the results of a rapid fetal fibronectin test affects treatment decisions during the evaluation and treatment of possible preterm labor. Previous observational studies have suggested that a negative test might help to avoid unnecessary intervention. STUDY
DESIGN: This was a randomized study of women who were between 24 weeks and 34 weeks 6 days of gestation with symptoms of preterm labor and who were seen in three community hospitals. A rapid fetal fibronectin test was performed on all subjects. Patients were assigned randomly to a group whose results were known to physician or to a group whose results were not known. Treatment decisions were at the discretion of the physician.
RESULTS: One hundred eight samples were collected between September 2000 and December 2001. There were 10 positive fetal fibronectin tests. The overall prevalence of delivery within 2 weeks for the study population was 2.8%. For women who had negative fetal fibronectin test results, the hospital stay was not significantly shorter when the result was known (6.8 hours) than when it was not known (8.1 hours, P =.35). However, when the physician knew the fetal fibronectin status of women with a negative test result who were observed for >6 hours, the hospital stay was shortened 40%, to 22.7 hours from 37.8 hours (P =.04).
CONCLUSION: Fetal fibronectin testing may be able to supplement clinical judgment in the evaluation of the condition of patients with symptoms of preterm labor. The greatest benefit of fetal fibronectin testing might be for the patient whom the physician judges to be at high risk for imminent delivery. In such patients, the knowledge of a negative fetal fibronectin may shorten the hospital stay.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12824997     DOI: 10.1067/mob.2003.390

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  5 in total

1.  The utility of fetal fibronectin in asymptomatic singleton and twin pregnancies with a cervical length ≤ 10 mm.

Authors:  Noelia Zork; Moti Gulersen; Anne Mardy; Caroline Pessel; Sara Brubaker; Joy Vink; Cynthia Gyamfi-Bannerman; Cande V Ananth
Journal:  J Matern Fetal Neonatal Med       Date:  2019-01-13

2.  Fetal fibronectin testing for reducing the risk of preterm birth.

Authors:  Vincenzo Berghella; Gabriele Saccone
Journal:  Cochrane Database Syst Rev       Date:  2019-07-29

Review 3.  Predicting preterm birth: Cervical length and fetal fibronectin.

Authors:  Moeun Son; Emily S Miller
Journal:  Semin Perinatol       Date:  2017-09-19       Impact factor: 3.300

4.  An elevated amniotic fluid prostaglandin F2α concentration is associated with intra-amniotic inflammation/infection, and clinical and histologic chorioamnionitis, as well as impending preterm delivery in patients with preterm labor and intact membranes.

Authors:  Jee Yoon Park; Roberto Romero; JoonHo Lee; Piya Chaemsaithong; Noppadol Chaiyasit; Bo Hyun Yoon
Journal:  J Matern Fetal Neonatal Med       Date:  2015-12-15

5.  Cost-effectiveness of fibronectin testing in a triage in women with threatened preterm labor: alleviation of pregnancy outcome by suspending tocolysis in early labor (APOSTEL-I trial).

Authors:  Jolande Y Vis; Femke F Wilms; Martijn A Oudijk; Martina M Porath; Hubertina C J Scheepers; Kitty W M Bloemenkamp; Annemiek C Bolte; Jérôme Cornette; Jan B Derks; Johannes J Duvekot; Jim van Eyck; Anneke Kwee; Brent C Opmeer; Maria G van Pampus; Fred K Lotgering; Sicco A Scherjon; Krystyna M Sollie; Marc E A Spaanderman; Christine Willekes; Joris A M van der Post; Ben Willem J Mol
Journal:  BMC Pregnancy Childbirth       Date:  2009-09-01       Impact factor: 3.007

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.